SG10201911989SA - Biomarkers associated with lsd1 inhibitors and uses thereof - Google Patents
Biomarkers associated with lsd1 inhibitors and uses thereofInfo
- Publication number
- SG10201911989SA SG10201911989SA SG10201911989SA SG10201911989SA SG10201911989SA SG 10201911989S A SG10201911989S A SG 10201911989SA SG 10201911989S A SG10201911989S A SG 10201911989SA SG 10201911989S A SG10201911989S A SG 10201911989SA SG 10201911989S A SG10201911989S A SG 10201911989SA
- Authority
- SG
- Singapore
- Prior art keywords
- biomarkers associated
- lsd1 inhibitors
- lsd1
- inhibitors
- biomarkers
- Prior art date
Links
- 229940123628 Lysine (K)-specific demethylase 1A inhibitor Drugs 0.000 title 1
- 239000000090 biomarker Substances 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382310 | 2015-06-12 | ||
| EP15382369 | 2015-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201911989SA true SG10201911989SA (en) | 2020-02-27 |
Family
ID=56345081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201911989SA SG10201911989SA (en) | 2015-06-12 | 2016-06-10 | Biomarkers associated with lsd1 inhibitors and uses thereof |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20180284095A1 (en) |
| EP (1) | EP3307909A1 (en) |
| JP (3) | JP6855466B2 (en) |
| KR (2) | KR20180011331A (en) |
| CN (2) | CN107849611A (en) |
| AU (2) | AU2016275702A1 (en) |
| BR (1) | BR112018075310A2 (en) |
| CA (1) | CA2987876A1 (en) |
| CY (1) | CY1121988T1 (en) |
| DK (1) | DK3307267T3 (en) |
| HR (1) | HRP20191121T1 (en) |
| HU (1) | HUE043954T2 (en) |
| IL (2) | IL256208A (en) |
| LT (1) | LT3307267T (en) |
| MX (2) | MX2017015922A (en) |
| MY (1) | MY190849A (en) |
| PT (1) | PT3307267T (en) |
| RU (1) | RU2768120C2 (en) |
| SG (1) | SG10201911989SA (en) |
| SM (1) | SMT201900353T1 (en) |
| TR (1) | TR201909353T4 (en) |
| WO (2) | WO2016198649A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3736265A1 (en) | 2011-10-20 | 2020-11-11 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| EP3090998A1 (en) | 2015-05-06 | 2016-11-09 | F. Hoffmann-La Roche AG | Solid forms |
| SG10201911989SA (en) * | 2015-06-12 | 2020-02-27 | Oryzon Genomics Sa | Biomarkers associated with lsd1 inhibitors and uses thereof |
| CN109195593A (en) | 2016-03-15 | 2019-01-11 | 奥莱松基因组股份有限公司 | For treating the combination of the LSD1 inhibitor of solid tumor |
| SG10201913290QA (en) | 2016-03-15 | 2020-03-30 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for the treatment of hematological malignancies |
| SI3307267T1 (en) | 2016-06-10 | 2019-08-30 | Oryzon Genomics, S.A. | Multiple sclerosis treatment |
| JP2019128317A (en) * | 2018-01-26 | 2019-08-01 | 学校法人同志社 | Marker and kit for diagnosing multiple sclerosis |
| SG11202010124SA (en) * | 2018-05-04 | 2020-11-27 | Oryzon Genomics Sa | Stable pharmaceutical formulation |
| EP4024049A4 (en) * | 2019-12-19 | 2023-09-20 | Daegu Gyeongbuk Institute Of Science and Technology | Biomarker composition for diagnosing mild cognitive impairment using nasal fluid sample, and method for diagnosing mild cognitive impairment using same |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| AU6168396A (en) * | 1995-06-07 | 1996-12-30 | Athena Neurosciences, Inc. | Method for identifying alzheimer's disease therapeutics usin g transgenic animal models |
| EP1193261A1 (en) * | 2000-10-02 | 2002-04-03 | Warner-Lambert Company | New thiadiazoles and their use as phosphodiesterase-7 inhibitors |
| WO2007021839A2 (en) | 2005-08-10 | 2007-02-22 | Johns Hopkins University | Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors |
| EP2142287A4 (en) | 2007-04-13 | 2012-05-23 | Univ Johns Hopkins | INHIBITORS OF LYSINE-SPECIFIC DEM ETHYLASE |
| EP2361242B1 (en) | 2008-10-17 | 2018-08-01 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
| EP2389362B1 (en) | 2009-01-21 | 2019-12-11 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
| US8895526B2 (en) * | 2009-03-27 | 2014-11-25 | Cold Spring Harbor Laboratory | Identification of RNAI targets and use of RNAI for rational therapy of chemotherapy-resistant leukemia and other cancers |
| US8389580B2 (en) | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
| EP2258865A1 (en) * | 2009-06-05 | 2010-12-08 | Universitätsklinikum Freiburg | Lysine-specific demethylase 1 (LSD1) is a biomarker for breast cancer |
| WO2010143582A1 (en) | 2009-06-11 | 2010-12-16 | 公立大学法人名古屋市立大学 | Phenylcyclopropylamine derivatives and lsd1 inhibitors |
| US9708255B2 (en) | 2009-08-18 | 2017-07-18 | Robert A. Casero | (bis)urea and (bis)thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders |
| JP5699152B2 (en) | 2009-09-25 | 2015-04-08 | オリゾン・ジェノミックス・ソシエダッド・アノニマOryzon Genomics S.A. | Lysine-specific demethylase-1 inhibitors and uses thereof |
| US8946296B2 (en) | 2009-10-09 | 2015-02-03 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use |
| WO2011131697A1 (en) | 2010-04-19 | 2011-10-27 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
| CN102985402B (en) | 2010-04-20 | 2015-04-29 | 罗马大学 | Tranylcypromine derivatives as inhibitors of histone demethylase LSD1 and/or LSD2 |
| EP2598480B1 (en) | 2010-07-29 | 2019-04-24 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| EP3375775A1 (en) * | 2010-07-29 | 2018-09-19 | Oryzon Genomics, S.A. | Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use |
| US9527805B2 (en) | 2010-09-10 | 2016-12-27 | Robert A. Casero | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders |
| WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| PE20141322A1 (en) | 2011-03-25 | 2014-10-05 | Glaxosmithkline Intellectual Property (N 2) Limited | CYCLOPROPYLAMINES AS INHIBITORS OF LYSINE-SPECIFIC DESMETILASE 1 |
| GEP201606559B (en) | 2011-08-09 | 2016-10-25 | Takeda Pharmaceuticals Co | Cyclopropaneamine compound |
| SG2014009609A (en) | 2011-08-15 | 2014-05-29 | Univ Utah Res Found | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhiitors |
| EP3736265A1 (en) | 2011-10-20 | 2020-11-11 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| EP2776394B1 (en) | 2011-10-20 | 2018-12-26 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| CN105051005B (en) | 2012-10-12 | 2017-06-13 | 武田药品工业株式会社 | Cyclopropylamine compounds and uses thereof |
| US9388123B2 (en) | 2012-11-28 | 2016-07-12 | Kyoto University | LSD1-selective inhibitor having lysine structure |
| EP2740474A1 (en) | 2012-12-05 | 2014-06-11 | Instituto Europeo di Oncologia S.r.l. | Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a |
| CN103054869A (en) | 2013-01-18 | 2013-04-24 | 郑州大学 | Application of amino dithio formic ester compound with triazolyl in preparing medicine taking LSD1 (Lysine Specificity Demethylase 1) as target |
| WO2014164867A1 (en) | 2013-03-11 | 2014-10-09 | Imago Biosciences | Kdm1a inhibitors for the treatment of disease |
| US9918983B2 (en) | 2013-05-30 | 2018-03-20 | The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas | Suicidal LSD1 inhibitors targeting SOX2-expressing cancer cells |
| SG11201510376QA (en) | 2013-06-19 | 2016-01-28 | Univ Utah Res Found | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors |
| CN103319466B (en) | 2013-07-04 | 2016-03-16 | 郑州大学 | Containing the 1,2,3-triazoles-dithiocarbamates compound of tonka bean camphor parent nucleus, preparation method and application thereof |
| BR112016002496B1 (en) | 2013-08-06 | 2022-07-12 | Imago Biosciences Inc. | COMPOUND AND PHARMACEUTICAL COMPOSITION |
| US9186391B2 (en) | 2013-08-29 | 2015-11-17 | Musc Foundation For Research Development | Cyclic peptide inhibitors of lysine-specific demethylase 1 |
| US9556170B2 (en) | 2013-08-30 | 2017-01-31 | University Of Utah Research Foundation | Substituted-1H-benzo[d]imidazole series compounds as lysine-specific demethylase 1 (LSD1) inhibitors |
| SMT202300014T1 (en) | 2013-12-11 | 2023-05-12 | Celgene Quanticel Research Inc | Inhibitors of lysine specific demethylase-1 |
| EP3102034A4 (en) | 2014-02-07 | 2017-07-12 | MUSC Foundation For Research Development | Aminotriazole- and aminotetrazole-based kdm1a inhibitors as epigenetic modulators |
| CR20160395A (en) | 2014-02-13 | 2016-12-20 | Incyte Corp | CYCLOPROPILAMINS AS INHIBITORS OF LSD1 |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| MY183499A (en) | 2014-02-13 | 2021-02-22 | Incyte Corp | Cyclopropylamines as lsd1 inhibitors |
| ES2672797T3 (en) | 2014-02-13 | 2018-06-18 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| CN106458856A (en) | 2014-03-07 | 2017-02-22 | 约翰霍普金斯大学 | Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs) |
| CN103893163B (en) | 2014-03-28 | 2016-02-03 | 中国药科大学 | The application of 2-([1,1 '-biphenyl]-4-base) 2-oxoethyl 4-((the chloro-4-aminomethyl phenyl of 3-) is amino)-4-oxobutanoic acid esters in preparation LSD1 inhibitor medicaments |
| NZ725262A (en) | 2014-04-11 | 2023-01-27 | Takeda Pharmaceuticals Co | Cyclopropanamine compound and use thereof |
| CN103961340B (en) | 2014-04-30 | 2019-06-25 | 南通中国科学院海洋研究所海洋科学与技术研究发展中心 | A kind of LSD1 inhibitor and its application |
| AU2015253040B2 (en) | 2014-05-01 | 2020-04-09 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
| EP3148974B1 (en) | 2014-05-30 | 2018-09-26 | Istituto Europeo di Oncologia S.r.l. | Cyclopropylamine compounds as histone demethylase inhibitors |
| CN104119280B (en) | 2014-06-27 | 2016-03-16 | 郑州大学 | Containing the pyrimidine derivatives of amino urea and Terminal Acetylenes structural unit, preparation method and application |
| HUE050564T2 (en) | 2014-06-27 | 2020-12-28 | Celgene Quanticel Res Inc | Lysine-specific demethylase-1 inhibitors |
| SI3511319T1 (en) | 2014-07-03 | 2023-10-30 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
| SG11201700007YA (en) | 2014-07-03 | 2017-01-27 | Celgene Quanticel Res Inc | Inhibitors of lysine specific demethylase-1 |
| US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
| US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
| US9695168B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| EP2993175A1 (en) | 2014-09-05 | 2016-03-09 | IEO - Istituto Europeo di Oncologia Srl | Thienopyrroles as histone demethylase inhibitors |
| BR112017004334A2 (en) | 2014-09-05 | 2018-08-07 | Celgene Quanticel Res Inc | lysine-1 specific demethylase inhibitors. |
| SG10201911989SA (en) * | 2015-06-12 | 2020-02-27 | Oryzon Genomics Sa | Biomarkers associated with lsd1 inhibitors and uses thereof |
-
2016
- 2016-06-10 SG SG10201911989SA patent/SG10201911989SA/en unknown
- 2016-06-10 EP EP16734564.4A patent/EP3307909A1/en not_active Withdrawn
- 2016-06-10 JP JP2018516634A patent/JP6855466B2/en not_active Expired - Fee Related
- 2016-06-10 CA CA2987876A patent/CA2987876A1/en not_active Abandoned
- 2016-06-10 MX MX2017015922A patent/MX2017015922A/en unknown
- 2016-06-10 CN CN201680045398.8A patent/CN107849611A/en active Pending
- 2016-06-10 AU AU2016275702A patent/AU2016275702A1/en not_active Abandoned
- 2016-06-10 US US15/735,377 patent/US20180284095A1/en not_active Abandoned
- 2016-06-10 KR KR1020187001221A patent/KR20180011331A/en not_active Withdrawn
- 2016-06-10 WO PCT/EP2016/063368 patent/WO2016198649A1/en not_active Ceased
-
2017
- 2017-06-09 BR BR112018075310-6A patent/BR112018075310A2/en not_active Application Discontinuation
- 2017-06-09 HU HUE17735004A patent/HUE043954T2/en unknown
- 2017-06-09 RU RU2019100037A patent/RU2768120C2/en active
- 2017-06-09 JP JP2017565305A patent/JP6411680B1/en not_active Expired - Fee Related
- 2017-06-09 SM SM20190353T patent/SMT201900353T1/en unknown
- 2017-06-09 MX MX2017015921A patent/MX2017015921A/en active IP Right Grant
- 2017-06-09 LT LTEP17735004.8T patent/LT3307267T/en unknown
- 2017-06-09 PT PT17735004T patent/PT3307267T/en unknown
- 2017-06-09 HR HRP20191121TT patent/HRP20191121T1/en unknown
- 2017-06-09 TR TR2019/09353T patent/TR201909353T4/en unknown
- 2017-06-09 DK DK17735004.8T patent/DK3307267T3/en active
- 2017-06-09 KR KR1020187001123A patent/KR102372194B1/en not_active Expired - Fee Related
- 2017-06-09 MY MYPI2017001810A patent/MY190849A/en unknown
- 2017-06-09 AU AU2017277751A patent/AU2017277751B2/en not_active Ceased
- 2017-06-09 WO PCT/EP2017/064206 patent/WO2017212061A1/en not_active Ceased
- 2017-06-09 CN CN201780002630.4A patent/CN107921029B/en not_active Expired - Fee Related
- 2017-12-10 IL IL256208A patent/IL256208A/en unknown
- 2017-12-10 IL IL256207A patent/IL256207B/en unknown
-
2018
- 2018-09-21 JP JP2018177879A patent/JP2019023202A/en active Pending
-
2019
- 2019-06-26 CY CY20191100663T patent/CY1121988T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201908301B (en) | Biomarkers and uses thereof | |
| IL277299B (en) | Cyclopropylamines as lsd1 inhibitors | |
| IL277167B (en) | Cyclopropylamines as lsd1 inhibitors | |
| IL260217B (en) | Lsd1 inhibitors | |
| IL277239B (en) | Mdm2 inhibitors and combinations thereof | |
| GB201605126D0 (en) | Inhibitors and their uses | |
| IL256208A (en) | Biomarkers associated with lsd1 inhibitors and uses thereof | |
| SG10201911204WA (en) | Autotaxin inhibitors and uses thereof | |
| GB201400521D0 (en) | Biomarker and uses thereof | |
| HUE063848T2 (en) | Lsd1 inhibitors and medical uses thereof | |
| IL256096B (en) | Inhibitor of igfbp3/tmem219 axis and diabetes | |
| IL256020B (en) | Igfbp3 and uses thereof | |
| IL254916B (en) | Inhibitors and their uses | |
| IL261906A (en) | Biomarkers of proteopathies and uses thereof | |
| GB201512133D0 (en) | Biomarkers | |
| GB201708741D0 (en) | Biomarkers and uses thereof | |
| GB201719565D0 (en) | Biomarker and uses thereof | |
| HK1263032A1 (en) | Lsd1 inhibitors | |
| GB201505975D0 (en) | Inhibitors and their uses | |
| GB201505971D0 (en) | Inhibitors and their uses | |
| AU2014904616A0 (en) | Biomarkers and uses thereof | |
| GB201519704D0 (en) | Biomarkers | |
| GB201513683D0 (en) | Biomarkers | |
| GB201505884D0 (en) | Transcription factors and uses thereof | |
| GB201509908D0 (en) | Methods and kits |